- Patent Title: JAK kinase inhibitor compounds for treatment of respiratory disease
-
Application No.: US17688001Application Date: 2022-03-07
-
Publication No.: US11718616B2Publication Date: 2023-08-08
- Inventor: Paul R. Fatheree , John R. Jacobsen , Anne-Marie Beausoleil , Gary E. L. Brandt , Melissa Fleury , Lan Jiang , Cameron Smith , Steven D. E. Sullivan , Lori Jean Van Orden , Pierre-Jean Colson , Gene Timothy Fass , Miroslav Rapta , Noah Benjamin , Marta Dabros , Venkat R. Thalladi
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agency: Sheppard Mullin Richter & Hampton LLP
- The original application number of the division: US16689706 2019.11.20
- Main IPC: A61K31/437
- IPC: A61K31/437 ; A61K31/416 ; A61P43/00 ; A61P11/06 ; A61P11/00 ; C07D471/04

Abstract:
The invention provides compounds of formula (I):
wherein X is
and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
wherein X is
and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
Public/Granted literature
- US20220306624A1 JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE Public/Granted day:2022-09-29
Information query
IPC分类: